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IRON IS A MAJOR COMPONENT of the Earth's crust, but its own chemistry greatly limits utilization and also sets the basis for its toxicity. Environmental iron exists in the ferric (Fe 3ϩ ) form, which is almost insoluble in water at neutral pH. In addition, iron, as a polar hydrophilic metal ion, is unable to cross membranes. Therefore, specialized transport systems and membrane carriers have evolved in humans to maintain iron in a "soluble" state suitable for circulation in the bloodstream [i.e., bound to serum transferrin (Tf)] or to transfer it across cell membranes [through metal transporters such as divalent metal transporter 1 (DMT1) or ferroportin1/IREG1/MTP-1 (see below)] for tissue utilization. The capacity of readily exchanging electrons in aerobic conditions makes iron essential for fundamental cell functions, such as DNA synthesis, transport of oxygen and electrons, and cell respiration. In fact, iron deprivation threatens cell survival, and iron deficiency in humans is a serious public health problem throughout the world. In these pathological states, iron supplementation is the only therapeutic option. On the other hand, because humans have no means to control iron excretion, excess iron, regardless of the route of entry, accumulates in parenchymal organs and threatens cell viability. In fact, a number of disease states are pathogenetically linked to excess body iron stores, and iron removal therapy is an effective life-saving strategy in such circumstances. In every cell during its normal life in aerobic conditions, a small amount of the consumed oxygen is reduced in a specific way, yielding a variety of highly reactive chemical entities collectively called reactive oxygen species (ROS). Transition metal ions such as iron, having frequently unpaired electrons, are excellent catalysts, and play a decisive role in the generation of the very reactive species from the less reactive ones; for instance, by catalyzing the formation of hydroxyl radicals from reduced forms of O 2 . Therefore, the modulation of "free iron" availability and appropriate sequestration of iron is the main means by which cells keep ROS levels under strict control. In this vein, to avoid oxidative stress and cell damage, cells have developed systems to adjust intracellular iron concentration to levels that are adequate for their metabolic needs but below the toxicity threshold.
Iron homeostasis. More than two-thirds of the body's iron content (3-5 g in healthy adult humans) is incorporated into hemoglobin in developing erythroid precursors and mature red cells and depends on receptormediated endocytosis of diferric Tf bound to Tf receptors [Tf receptor 1 (TfR1)] (11) . A new Tf receptor has been recently identified [Tf receptor 2 (TfR2)], which can bind diferric Tf but whose function and properties have not been completely understood (47) . Fe 2ϩ Tf binds to TfR1 on the surface of erythroid precursors; Fe 2ϩ Tf/TfR1 complexes localize to clathrin-coated pits, which invaginate to form specialized endosomes. A proton pump decreases the pH within the endosomes, leading to conformational changes in proteins that result in the release of iron from Tf. The iron transporter DMT1 moves iron across the endosomal membrane to enter the cytoplasm (31) . Meanwhile, apo-Tf and TfR1 are recycled to the cell surface, where each can be used for further cycles of iron binding and iron uptake. In erythroid cells, most iron moves into mitochondria, where it is incorporated into protoporphyrin to make heme. Because the erythron requires 20 mg of iron daily but only 1-2 mg of iron normally enters the body each day through the intestine, iron is recycled continually by breakdown of effete red cells in macrophages followed by iron loading onto serum Tf and delivery to bone marrow for reincorporation into red cells (21) . Most of the remaining body iron, ranging from 0.5 to 1 g, is found in hepatocytes that store unutilized iron into specialized proteins [i.e., ferritin (Ft) and hemosiderin]. By contrast ϳ1-2 mg of iron are lost from the body each day by processes such as sloughing of skin and menstruation. This lost iron is replaced by absorption of dietary iron through the mucosa of the duodenum.
This simple model implies fundamental concepts that are key to understanding iron metabolism and its abnormalities in hemochromatosis (HC): 1) the erythron's requirement for iron is a priority and dominates body iron trafficking; 2) to assist hemoglobin synthesis, the release of reticuloendothelial (RE; macrophage) cell iron and iron loading onto circulating Tf is key; 3) duodenal epithelial cells must be informed of the erythron's needs and, possibly, of the state of body iron deposits. Although, in recent years, most of the effector proteins of iron uptake, transfer, and storage have been identified in discrete tissue (see also Table  1 ), the signals that orchestrate in a coordinate fashion the expression of these proteins and the relevant biochemical pathways that underlie the cross-talk between bone marrow, RE cells, and the intestine are still elusive.
"Sensing" iron and controlling its trafficking at the cellular level. As discussed above, regulation of iron (and oxygen) levels in the cell are critical for cell survival or death. Consequently, sensing iron and oxygen and controlling their levels is vital for living organisms.
Very early in earth's history, in the absence of oxygen, elemental iron and sulfur could freely interact and assemble spontaneously. The iron-sulfur proteins, in which the iron is at least partially coordinated by sulfur, are found in a wide range of organisms from bacteria to man (7) . In many of these proteins, the role of the cluster is to allow electron transfer, catalyze functions, or maintain structural integrity. Thus their chemical versatility and flexibility in catalytic and electron transfer reactions make them suitable for many fundamental functions (34) . These clusters, particularly the 4Fe-4S clusters, have the capacity to accept or donate single electrons, they are frequently found in enzymes in which single electrons must be supplied or removed to catalyze transformations of substrate, as is the case in a number of mammalian respiratory chain proteins, such as succinate dehydrogenase, NADH dehydrogenase, and the cytochrome bcl complex. One major function of the Fe-S clusters, due to their chemistry, is sensing oxygen and iron. This is the case of the fumarate nitrate reduction protein (FNR) of Escherichia coli, an oxygen sensor, in which the loss of integrity of the cluster in the presence of oxygen is the key to sensing. In response to lowered oxygen tension, the metabolism of E. coli switches from use of oxygen to use of alternative terminal electron acceptors such as fumarate and nitrate, a change that requires the simultaneous transcriptional activation of over 50 genes of anaerobic metabolism (39) . In the absence of oxygen, FNR binds to promoters of the genes of anaerobic metabolism and activates transcription. In the presence of oxygen, the cluster disintegrates, and the protein no longer binds DNA. Thus FNR provides a clear example in which a reactive iron-sulfur cluster is used to sense concentrations of the destabilizing agent, oxygen. What about sensing of iron? As mentioned, iron is essential for cell division and growth, but tight regulation of iron uptake and distribution is necessary because excess iron can be toxic, particularly because iron species and oxygen can interact to form ROS, including superoxide and hydroxyl radicals. Thus iron uptake and storage within most cells is carefully regulated by a set of genes that is highly conserved in mammalian cells to maintain an adequate substrate while also minimizing the pool of potentially toxic free iron. Proper sensing of iron and oxygen in the aerobic environment and the need for a tight control of iron and oxidants are also crucial for the cell to adapt to unfavorable and hazardous situations.
The iron regulatory proteins sense iron and control proteins involved in iron homeostasis. Recent investigations suggest that a single genetic regulatory system, based on iron-sulfur interactions, senses iron and "orchestrates" all these aspects at the posttranscriptional level: the iron regulatory proteins (IRPs) (81) . The IRPs represent the sensors of cytoplasmic iron and the controllers of the main proteins involved in iron homeostasis: Ft, TfR1, ferroportin1/Ireg1/MTP1, and the divalent metal transporter (DMT1; previously named Nramp2 and DCT1). These proteins are used by cells to adjust intracellular iron concentration to levels that are adequate for their metabolic needs but below the toxicity threshold. Ft and TfR1 hat have been found to contain at the untranslated region (UTR) of the mRNA noncoding sequences [i.e., the iron-responsive elements (IRE)] that are recognized by two cytoplasmic IRPs (IRP-1 and IRP-2). The IRPs belong to the aconitase superfamily: by means of an Fe-S clusterdependent switch, IRP-1 can function as an mRNA binding protein or as an enzyme that converts citrate to isocitrate (43) . Although structurally and functionally similar to IRP-1, IRP-2 does not seem to assemble a cluster or to possess aconitase activity; moreover, it has a distinct pattern of tissue expression and is modulated by means of proteasome-mediated degradation. In response to fluctuations in the level of the "free iron pool," IRPs act as key regulators of cellular iron homeostasis as a result of the translational control of the expression of a number of iron genes. Conversely, various agents and conditions may affect IRP activity, thereby modulating iron and oxygen radical levels in different pathobiological settings (15) . Mammalian cells react to iron deficiency by presenting a higher number of TfR1 at the cell surface to internalize ironladen Tf. At the same time, the synthesis of the iron storage protein Ft is halted to enhance metal availability. The opposite is true when iron overload occurs: TfR1 is downregulated to stop iron uptake, and Ft synthesis is increased to sequester excess iron in newly formed Ft shells. When iron is scarce, Ft and TfR1 mRNAs are specifically recognized and bound by the active form of IRP that blocks Ft translation (IRE at the 5Ј UTR of the mRNA) and stabilizes TfR1 mRNAs (IREs at the 3Ј UTR of the mRNA), respectively. On the contrary, when iron is abundant, IRPs are devoid of mRNA binding activity and target transcripts are freely accessible to translation complexes (Ft mRNA) or nucleases for degradation (TfR1 mRNA). IRPs therefore control cell iron status by means of divergent but coordinated regulation of iron storage (Ft) and uptake (TfR1). Interestingly, the UTR of mRNA for important putative iron import and export proteins also carries IREs. Three groups have isolated and characterized the product of the SLC11A3 gene referred to as ferroportin1/IREG1/MTP1 (1, 25, 57) . The protein product is a putative multiple membrane-spanning transporter that has been shown to function as an iron exporter. The localization of Ferroportin1/Ireg1/MTP1 in cells and tissues is consistent with its proposed function of exporting iron from cells. The protein is found in the liver, predominantly in Kupffer cells (1, 25) , and on the basolateral membrane of polarized cells (25, 57) . The Ferroportin1/IREG1/MTP1 mRNA possesses an ironresponsive element in the 5Ј UTR that binds IRPs and confers iron-dependent regulation of luciferase in desferoxamine-treated COS7 cells (1) . However, the protein levels found in vivo under varying conditions of iron repletion are not entirely consistent with this type of regulation. Immunohistochemical staining for the iron exporter revealed strong reactivity in the Kupffer cells of iron-replete mice with weaker staining in iron-depleted mice, consistent with regulation through the IRPs (57). However, the reciprocal result was found in the duodenal epithelium; immunohistochemical staining was strong in iron-depleted mice and weaker in iron-replete mice (57) .
Functional IREs are also present in one of the two isoforms (i.e., the isoform that is predominant in the intestine) of the DMT1/Nramp2 (38, 73) . DMT1 function and regulation have been reviewed recently (4). DMT1 is a proton symporter that transports ferrous iron and other divalent metals from the intestinal lumen into the enterocyte or from the endosomes to the cytoplasm in erythroid cells and other cell types (32, 40) . The IRE is at the 3Ј UTR of the DMT1 mRNA, which suggests that low iron would stabilize the mRNA, as in the case of TfR1 mRNA.
Paradoxically, the mRNA coding for the longawaited protein in iron metabolism, the HC gene product HFE, does not contain IREs nor is it known to be regulated by iron status. Yet, as discussed below, HFE has a dramatic impact on cell iron trafficking and, indirectly, on intestinal iron absorption.
The HC (HFE) gene product binds TfR1. HC represents one of the most common single-gene hereditary diseases (3) . A cornerstone of HC genetics was laid in 1996, with the isolation of the HC gene, now called HFE (26) . The majority of HC patients carry the same mutation, resulting in a change from cysteine at position 282 to tyrosine (C282Y) in the HFE protein (59) . The human HFE protein is closely related to the major histocompatibility complex (MHC) class I molecules. The C282Y mutation disrupts a critical disulfide bond in the ␣ 3 -domain of the HFE protein and abrogates binding of the mutant HFE protein to ␤ 2 -microglobulin (␤ 2 -M) (28) . This results in reduced transport to and expression on the cell surface (90) . Conversely, mice lacking ␤ 2 -M show a hemochromatotic phenotype (84) . The HFE knockout and knockin (carrying only the C282Y mutation) mice recapitulate the human disease (54, 93) .
The first indication that HFE can influence iron homeostasis came with the discovery that it binds TfR1 with an affinity close to that of Tf, reducing the affinity of the TfR1 for Tf and competing with Tf binding (27, 51) . In transfected HeLa cells, HFE is found in Tfpositive intracellular compartments (37) . A recent study has confirmed that HFE protein binds specifically to the classic form of TfR and TFR1, but not to TfR2, which is highly expressed in the liver and in peripheral blood mononuclear cells and is devoid of IRE in the mRNA (92) . In addition, in an elegant study, it has been shown that binding to TfR is not required for targeting of HFE to the basolateral membrane but is required for HFE to be transported to Tf-positive endosomes and for regulation of intracellular iron homeostasis in cultured cells (79) . This reinforces the idea that the biological effect of HFE on TfR may be exerted in the endosomal compartment where iron is released from the TfR-Tf complex and not necessarily at the cell surface. At the tissue level, HFE appears to be preferentially expressed in duodenal crypt cells and Kupffer cells of the liver, mainly in the perinuclear compartment (6, 68) .
The free iron pool and the IRPs control cell iron import, storage, and export. In the simple scheme depicted above involving proteins devoted to iron uptake, transfer, store, and release, the IRP system may be used by the cell to sense iron and to efficiently coordinate its trafficking. However, as demonstrated in other settings, protein of iron metabolism, including Ft and TfR, may undergo additional regulatory mechanisms through transcriptional and posttranscriptional pathways depending on the specific cell context (15) . In fact, ferroportin1/IREG1/MTP1 is also controlled at the level of mRNA accumulation in the hypotransferrinemic mice (58) or intracellular protein trafficking (1) . Similarly, DMT1 subcellular localization has been also found to vary in the duodenum according to the iron status in iron-loaded or -depleted rats (88) . In general, it is the fluctuation of the intracellular iron pool, through the IRP system or directly through transcriptional/posttranscriptional controls, that signals the complex genetic machinery controlling iron homeostasis. This may be true for epithelial cells devoted to absorption or storage of iron or mesenchymal cells involved in iron recycling. In different cell types, the system may operate in different ways depending on the relative function of the target protein in the particular cell. For instance, rapidly growing cells (e.g., stem cells in the intestinal crypts) or erythroid cells depend exclusively on TfR expression to provide iron for growth or hemoglobin synthesis, respectively. Most likely, they do not need iron-export systems. On the other hand, liver parenchymal cells are used as "storage" cells; they are relatively quiescent and express very little TfR under normal conditions and none during iron overload (71) . In the hepatocytes, iron is stored in Ft that is able to accommodate 4,500 atoms of iron per molecule. When needed, hepatocytes export iron, possibly through ferroportin1/IRG1/MTP1, and may load circulating Tf to meet bone marrow needs. During iron overload, when TfR1 is further downregulated in the liver (71), a non-Tf bound form of iron appears in the bloodstream, which is taken up by the hepatocytes through mechanisms different from that of Tf-bound iron (13) . In addition, the recently described TfR2 (47), which is capable of delivering Tf iron, appears to be normally expressed during liver iron overload (33) . These mechanisms ensure that the liver serves as a physiological sink for iron during iron overload states (see also Fig. 1 ).
RE cells of the liver and the spleen play a central role in iron metabolism that goes beyond the simple iron storage function. They process Ͼ80% of the iron entering the plasma each day and thus represent a fundamental compartment in systemic iron metabolism (30) . During pathophysiological states, such as chronic inflammation and anemia of chronic diseases (ACD), the role of RE cells of the macrophage lineage is pivotal in the systemic changes of iron metabolism leading, for instance, to hypoferremia, mainly through enhanced iron retention of circulating iron in RE cells (48) . The iron derived from phagocytosis of senescent red blood cells is released from the heme moiety possibly through the catabolic activity of heme oxygenase. However, the exact molecular events underlying the iron-release process are obscure, and the cross-talk between the heme-derived iron pool and the cytoplasmic free iron/ IRP pool within the RE cells has not been deciphered.
The "free iron pool" and the IRPs control intestinal iron absorption. In polarized cells involved in iron extraction from the external milieu (syncytiotrophoblasts in the placenta and epithelial cells in the duodenum) iron-protein expression and regulation is instrumental to the specific role of the cell.
In intestinal cells, iron must be transferred across two lipid bilayers: the apical and the basolateral membrane. In addition, a vertical functional axis exists in the intestinal villus, where cells at the tip or at the bottom (crypts) of the villus have a completely different pattern of expression of iron carriers and, consequently, a different role in iron transport. Within the crypts of the intestine are multipotent precursor cells, actively proliferating and expressing TfR1, which eventually migrate onto the villus and differentiate into absorbing enterocytes. (44, 75) . Crypt cells do not absorb dietary iron; in fact, they do not express appreciable amounts of the apical iron transporter DMT1 (17) or the basolateral transporter ferroportin (25, 57) . However, seemingly to erythroid precursors, they avidly import iron from the circulation through a highly efficient TfR1-driven iron-uptake system, and all iron is retained by the cell to fulfill high growth demands. Iron not used to sustain growth may be stored into Ft and reaches, as such, the higher portion of the villus after maturation-differentiation of the enterocytes. The mature enterocytes of the villus are specialized for absorption and transport of dietary iron (Fig. 1) . Indeed they are equipped with iron carriers and coupled reductase or ferroxidase activities at the apical and basolateral membrane. Dietary free iron first undergoes reduction from the ferric (Fe 3ϩ ) to the ferrous (Fe 2ϩ ) state on the luminal surface of the proximal small intestine through the recently discovered duodenal cytochrome b (Dcytb) (56) . Dcytb is probably the protein responsible for iron reduction at the brush border of enterocytes, because antibodies against Dcytb are able to block intestinal ferric reductase activity (56) . Once reduced, iron is transported into the enterocytes by the apical transporter DMT1 (4). Iron can also be absorbed by the heme-iron uptake pathway that functions as a very efficient means of iron uptake, but the molecular mechanisms of transport into or across the intestinal epithelium have not yet been elucidated. Finally, a mucin-integrin-mobilferrin pathway has also been postulated as a possible means of iron uptake (20) . Once in the enterocyte, iron may be stored within the cell as Ft and lost with exfoliation of the intestinal epithelium (36) or transferred across the basolateral membrane to the plasma, possibly by the transport protein ferroportin1/Ireg1/MTP1. Hephaestin (89), a ceruloplasmin-like molecule, may assist the transfer of iron to the plasma through the oxidation of Fe 2ϩ to Fe 3ϩ . Hephaestin is the gene mutated in the sex-linked anemia (SLA) mice, in which efflux of iron through the basolateral membrane and into the plasma is inhibited. Hephaestin expression is restricted to cells of the villus, sparing crypt cells, and is associated to membranes (cell membrane and/or membrane vesicles) (50) . Although hephaestin certainly plays a crucial role in iron efflux from the enterocyte, the actual transporter that shares the iron efflux pathway with hephaestin is not yet known. Ceruloplasmin, itself, has ferroxidase activity, and is involved in the release of iron from cells and, possibly, in loading iron onto circulating Tf (41, 63, 66) . Accordingly, patients with aceruloplasminemia have accumulation of iron in neural and glial cells of the brain (particularly the basal ganglia and dentate nucleus), hepatocytes, and pancreatic islet cells (42) .
Within this framework, the most likely hypothesis is that the free iron pool within the mature enterocyte is the key regulator of iron absorption. In early studies, it was suggested that this iron pool dictates, through IRPs and additional transcriptional and posttranscriptional mechanisms, the level of expression of the apical and basolateral iron transporters and iron transfer through the enterocyte (69, 70) . Because the compartment of the differentiated iron-absorbing enterocytes (devoid of TfR-HFE) is functionally "isolated" from the compartment of body iron and unable to be informed of the body iron status, it is the iron status determined in the precursor crypt cells (enriched in TfR-HFE) that eventually "transfer" the information on body iron status to the mature enterocytes (Fig. 1) . This was shown in early studies using 59 Fe in animal and following the radioactivity in the enterocytes as they ascend the villus during the life cycle (24) . In accordance with this model, it has been shown that duodenal IRP activity was inversely related to body iron status, being elevated in anemia and decreased in iron overload, which also implied that the iron pool of the enterocyte was low or high, respectively, in these conditions (69) . Accordingly, the expression of TfR in the crypts is inversely related to iron stores (2, 76) . If true, the apical and basolateral iron transporters should be up-and downregulated depending on iron and IRP status. Indeed, DMT1 and ferroportin activity have been reported to be increased in iron-deficient subjects and decreased in iron overload, suggesting that intestinal iron status may set the level of expression of iron transporters and, possibly, of their activity (94) .
One important addition to our understanding of iron homeostasis comes from the observation made in the hypotransferrinemic mice (gene symbol hpx). Homozygous hpx mice die from severe anemia early in life due to deficiency in serum Tf (9) . A similar phenotype is found in human atransferrinemia (9) . Anemia is due to inability to provide iron to erythroid precursors. This proves the importance of Tf (and TfR) for erythropoiesis. On the other hand, the hpx mice develop severe tissue iron overload due to increased iron absorption and delivery of non-Tf-bound iron to tissues. This indicates that 1) Tf (and TfR) is not essential for iron uptake in nonhematopoietic cells, 2) it is not directly involved in intestinal iron absorption, and 3) signals originating in the "erythron" are able to greatly enhance iron absorption despite body iron overload.
Sensing iron and controlling its trafficking at the BODY level. It is generally believed that the enterocyte receives signals from various tissues as to the relative repletion of iron stores. This regulatory mechanism of iron absorption is termed the "stores regulator" (29) . When the amount of iron found in body stores drops below a critical level, the stores regulator increases iron uptake until the reserves are replete again (23, 35, 45) . The opposite is true during iron overload. The stores regulator acts on a pathway that facilitates a slow accumulation of nonheme dietary iron (ϳ1 mg/ day) (85) and is able to change iron absorption rate to a limited extent. It has been postulated that soluble components might serve as store regulators: serum Ft, Tf, or the serum (soluble) TfR (29) . Recently, a new candidate has been put forth: hepcidin. Two groups searching for novel antimicrobial peptides independently discovered hepcidin. Krause et al. (49) purified the peptide from human blood (designating it liver- Fig. 1 . A model for the regulation of body iron homeostasis in physiology and pathophysiology, including hereditary hemochromatosis. A: in normal subjects iron is continuously recycled between the bone marrow and reticuloendothelial (RE) cells, with serum transferrin (Tf) acting as a shuttle to deliver iron to the erythron from RE cells and enterocytes. The iron not needed for erythropoiesis is stored mainly into the hepatocytes. In this "closed" system, a sufficient flux of iron toward the erythron is secured by the iron influx from the intestine, which basically matches the daily losses. The "information" on the erythron and body iron status is transferred to the crypt cells of the distal duodenum by Tf: the extent of Tf saturation with iron acts as the "signal" that is transferred through the transferrin receptor (TfR)/HFE pathway to the stem cells of the crypts. This sets the level of "free iron pool" in the crypt cell that will also be reflected in the mature enterocytes on differentiation and migration to the villus. The free iron pool through the iron regulatory proteins (IRP) and other transcriptional and posttranscriptional mechanisms will dictate the level of expression of apical and basolateral iron transporters in the mature enterocytes of the villus and, in turn, of iron absorption. B: in iron-deficiency anemia, the circulating iron-poor Tf will signal to RE cells the increased erythron demands prompting for iron release and diverting iron from the periphery, including intestinal cells, to the erythron. Due to low availability of circulating iron, the decreased free iron pool in crypt cells will signal the mature enterocyte to activate the iron uptake transfer machinery. C: during secondary iron overload (e.g., transfusion siderosis), iron-saturated Tf will cause the RE cells and crypt cells to retain iron; this will then downregulate iron carriers in the mature iron-replete enterocytes and decrease iron absorption. D: in hereditary hemochromatosis, due to the defective HFE and the faulty HFE/TfR pathway, both RE cells and crypt cells receive an incorrect signal of "iron deficiency" despite increasing saturation of circulating Tf with iron. This, paradoxically, will lead, as in a "true" iron-deficiency state, both macrophages and duodenal enterocytes to "release" more iron. Duodenal cells will accomplish this by activating the iron uptake transfer machinery. DMT1, divalent metal transporter 1. expressed antimicrobial peptide). Park et al. (67) isolated it from human urine, designating it hepcidin (hepatic bactericidal protein). Expression of hepcidin mRNA was nearly confined to the liver. The transcript encodes a precursor protein of 84 amino acids, including a putative 24-amino acid leader peptide, whereas the circulating form consists of only the COOH-terminal 25 amino acids. Due to significant antibacterial and antifungal activities of the COOH-terminal peptide, hepcidin was classified as a member of the cysteinerich, cationic, antimicrobial peptides, including the thionins and defensins (52). Nicolas et al. (64) found that mice developed iron overload consequent to targeted disruption of the gene encoding the transcription factor upstream stimulatory factor 2 (USF2). In the USF2 knockout mice, the character of iron overload resembled that of human HC. Specifically, the hepatic iron distribution is predominantly periportal, whereas the RE system is relatively spared from iron loading. In attempting to explain these findings, the investigators discovered that USF2 knockout mice fail to express either copy of the duplicated hepcidin genes immediately downstream of USF2, leading them to attribute the iron loading to absence of hepcidin. A link between hepcidin and iron homeostasis had been previously made by Pigeon et al. (72), who independently cloned the orthologous murine cDNA by differential screening for hepatic mRNAs overexpressed with iron overload. Northern blots confirmed that hepcidin mRNA is increased with dietary iron loading and also increased in ␤ 2 -M knockout mice. No iron-responsive elements were identified in the hepcidin transcript, so the mechanism for the change in mRNA content with change in iron status was unclear. This observation, coupled with the phenotype of the USF2 knockout mice, may lead to suggest a possible role for hepcidin in controlling iron homeostasis during inflammation and ACD: high hepcidin level would induce sequestration of iron in RE cells and downregulation of intestinal iron absorption. Nicolas et al. (64) speculated that TfR-2 mediates iron uptake by hepatocytes, which, in turn, modulates expression of hepcidin, which, in turn, interacts with HFE-TfR1 in the duodenal crypt cell to regulate dietary iron absorption. However, still some caution must be used, because, as also pointed out by Nicolas et al. (64) , it is possible that changes in expression of another gene on disruption of USF2 led to the observed phenotype.
The "erythropoietic regulator" is a second hypothesized regulator that does not directly respond to iron stores but only to the erythropoietic demand of the organism. In fact, individuals with normal or increased iron stores upregulate iron absorption as marrow iron requirements increase (29) . Because an increase in erythropoiesis alone is not enough to increase iron absorption, the imbalance between the rate of erythropoiesis of the marrow and its iron supply is thought to induce iron absorption (3). The absorptive pathway targeted by the erythropoietic regulator is probably distinct from the pathway targeted by the stores regulator, as evidenced by the rate of iron uptake that is significantly higher on bone marrow demands. Anemic individuals can absorb between 20 and 40 mg of iron per day, an increase much greater than that which the store regulator is capable of producing (29) . Like the store regulator, the erythropoietic regulator is hypothesized to be a soluble component of the plasma, because it must signal between the erythroid marrow and the intestine. Soluble TfR has been proposed as a candidate (19) . An additional factor that can play a role in controlling intestinal iron absorption is hypoxia. Early studies showed that hypoxia may act as an independent regulator and that animals with splenectomyobliterated erythroid activity and 89 Sr or with nephrectomy show increased iron absorption in response to hypoxia (77, 78) . Increased ferroportin1/IREG1/MTP1 may be the effector for this response of iron absorption. In fact, in the hpx mice, it is likely that a hypoxic stimulus may contribute to trigger indirectly enhanced intestinal iron transfer, possibly through ferroportin1/ IREG1/MTP1 overexpression (57) . Whether this regulatory pathway is truly distinct from the one induced by the erythropoietic regulator is uncertain.
In conclusion, soluble circulating factors are able to transfer to the crypt cells key information on the body iron status and bone marrow demands. The signaling pathways and molecular components involved in the modulation of iron absorption through any of these regulators remain to be determined. In the next chapter, a hypothetical model of regulation of iron homeostasis is proposed, in which the extent of saturation of circulating Tf with iron may serve as a "unifying regulator" of iron absorption in physiological and pathopysiological states, including HC.
HC: a disorder of the "store's regulator." Iron absorption is inappropriate to body iron stores in HC and steadily increases from birth despite expanding iron deposits (12) . Typically, in HC subjects, there is a positive iron balance of 1-2 mg of iron daily that during childhood and adolescence in male and in menstruated females does not cause marked iron accumulation due to high growth demands and iron losses, respectively. Afterwards, iron overload in the liver, pancreas, heart, and joints leads to cell damage and organ disease. After phlebotomy, as in normal subjects, a sharp increase in intestinal iron absorption occurs in HC. However, at variants with nonhemochromatotic subjects, iron absorption remains at a high rate for a long period of time (86) . This indicates that the absorption machinery is intrinsically normal in HC, whereas the feedback control from body stores is lost. In HC, the store's regulator may be unable to signal the intestine or fails to "see" the expanding iron store and interpret it as iron deficiency.
In view of the available data, any proposed model of HFE function in iron metabolism has to consider 1) the biochemical evidence (i.e., HFE interacts with TfR1), 2) the pattern of expression of TfR1 and HFE in vivo, and 3) the phenotype of human HC.
At the biochemical level, data from several tissue culture studies show that overexpression of HFE results in significant reduction in the rate of iron uptake, decrease in iron and Ft, and induction in TfR1 expression (22, 37, 46, 80, 82, 83) . The proposed mechanism of TfR inhibition by HFE is controversial. Initial studies (82) indicated that HFE does not reduce Tf uptake at saturating Tf concentrations or alter the cycling of the TfR1. Others showed a reduction in Tf uptake (83) or a reduction in the rate of Tf recycling to the cell surface (46) . Some caution should be used in extrapolating these in vitro data to the in vivo situation. Most of these studies have been carried out in vitro using concentrations of Fe 2ϩ Tf that is lower that that found in plasma (8-15 M) or using bovine serum Tf, which has a low affinity for human TfR1, or expressing inappropriately and nonphysiological levels of HFE. It is in fact clear that the stoichiometry of Tf, HFE, and TfR1, and their relative equilibrium in the cell may be critical in determining a biological effect. Studies of HFE and TfR1 in transfected cells and in solution suggest that stoichiometry is 1:2, or one HFE per Tf-receptor dimer (37, 51) . However, the crystal structure indicates that a 2:2 stoichiometry is also possible under very high concentrations of HFE (ϳ8 nM) (8) . The relative concentrations of HFE and TfR1 appear to be important also in vivo. Mice lacking HFE (or having the human HC C282Y HFE allele) and one TfR allele show more iron loading than HFE knockout mice (53) . HFE is mainly expressed in intestinal crypt cells and macrophages of the liver (Kupffer cells) in tissue-staining experiments with specific antibodies (6, 68) . TfR1 appears to be highly expressed in the crypts (55) . Although macrophages are believed to express low TfR1 and phagocytosis of erythrocytes accounts for the majority of iron acquired by these cells in vivo, TfR1-mediated uptake may also occur in culture (87) and in vivo (10) in macrophages. Therefore, judging from the results of the available studies, the relative equilibrium of HFE to TfR1 in duodenum and macrophages may be different in vivo, and this may have reflection on the function in the relevant tissue. In one of these studies, the expression of HFE in Kupffer cells of the liver was particularly strong (6) , and this might indicate a special role of HFE in these cells. In summary, although the in vitro observations did lead to the hypothesis that the function of HFE in vivo is to inhibit TfR1-mediated iron-Tf uptake, there are concerns due to intrinsic limitations of the in vitro approach. Moreover, the in vitro findings do not explain the HC phenotype: a mutated HFE should lead to iron overload, whereas in HC, tissues with the strongest HFE (and TfR1) expression are actually iron deficient (i.e., crypt cells and macrophages). In fact, in HC patients (14) and in murine models of HC (i.e., HFE and ␤ 2 -M knockout mice) (84, 93) , little metal is stored in macrophagic cells, and IRP activity in HC macrophages is inappropriately high, indicating a paradoxically low iron pool (14) . The accumulation of iron in parenchymal cells of the liver is most likely a passive phenomenon following increased circulating iron, because hepatocytes express very low TfR1 and no HFE and may be mediated by TfR2 and other carriers delivering the non-Tf-bound iron fraction (Fig. 1) . In a recent study by Montosi et al. (60) , it was demonstrated that a lower Fe 2ϩ -Tf accumulation is a primary defect of HC macrophages, persisting in vitro, and is corrected by expression of normal HFE. In this study, accumulation of 55 Fe delivered by 55 Fe Tf was significantly lower in macrophages from HC patients than from controls expressing wild-type HFE. When the HC macrophages were transfected to express wild-type HFE protein, the iron uptake was raised by 40-60%, indicating that the iron-deficient phenotype of HC macrophages is a direct effect of the HFE mutation. In agreement with this conclusion, in the HFE knockout mice, spleens are relatively resistant to dietary iron loading, possibly reflecting decreased accumulation of Tf-bound iron by the HFE Ϫ/Ϫ splenic macrophages (54) . Interestingly, the same phenomenon occurs in the intestine of HC patients. Some 30 years ago, Astaldi et al. (5) reported the absence of Ft bodies in intestinal cells in HC. Then, it was found that high activity of IRP was responsible for inappropriately low Ft in duodenal cells of HC patients (69, 70) . This again implies that also these cells are actually iron poor.
Paradoxically, the phenotype of HC in the intestine and RE system is identical to that of iron deficiency anemia (14, 69, 70) . Consequently, as in iron deficiency, the intestinal iron transporters DMT1 and ferroportin1/IREG1/MTP1 are activated in HC (94, 95) . Seemingly, the increased rate of low molecular weight iron release in RE cells from HC patients (62) may be due to a similar enhanced activity of iron export (through ferroportin1/IREG1/MTP1). At variance with anemia, the serum Tf saturation (a marker of enhanced body iron recycling) is high in HC: serum Tf saturation rises early in the disease before serum Ft (a marker of iron stores) increases. Eventually, 80-100% of the circulating Tf is saturated with iron in HC patients, whereas in normal subjects, only 20-40% of the Tf is iron loaded. The concentration of Tf in plasma is 30 M, and that of Fe 2ϩ Tf is 8-15 M. The K d of the Tf receptor is on the order of 3-9 nM, and therefore, there should be sufficient Fe 2ϩ Tf in the plasma of normal subjects to assure continuous saturation of TfR on the cell surface; the fact the cells do not become iron loaded may indicate that other mechanisms in addition to TfR1 numbers control iron uptake. There may be several proteins cycling with TfR in endosomes in addition to HFE, and they may interact with TfR and cooperate to modulate the delivery of Tf/TfR iron into the cell.
The rate of intestinal iron absorption is usually inversely related to the serum Tf saturation. Mice and humans that lack Tf expression become grossly loaded with iron due to uncontrolled absorption of iron from the gut (9). These results suggest that the main supply of iron to the intestinal crypt cell is from serum Tf. In early studies, it was shown that secondary polycythemia induced by changing atmospheric pressure led to depression of iron utilization for erythroid activity (91). This was followed by increased iron deposition in the gut and reduction of iron absorption. This stresses the role of plasma iron turnover (and saturation of serum Tf) in the control of iron absorption. Increased red blood cell production induces an increase in plasma iron turnover (with uploading of iron onto circulating Tf) that leads to a diversion of iron from the intestinal and RE cells to the bone marrow, with increased iron absorption. In conditions of low Tf saturation, the crypt becomes starved of iron, leading to activation of the genetic iron import-export machinery. When the plasma iron turnover decreases (and Tf saturation rises), more iron is diverted to the intestinal crypt cells, where the expansion of the free iron pool, once the cells differentiate to iron-absorbing enterocytes, downregulates the expression of iron carriers and decreases iron absorption (Fig. 1 ). In this model, macrophages have a central role. It has been estimated that macrophages in vivo deliver 10,000,000 atoms of iron each minute to circulating Tf (30) . The uptake of Fe 2ϩ Tf through TfR1 by macrophages may be the means for macrophages to be informed on the body iron status and erythroid demands. In the presence of low Tf saturation, as in iron deficiency, macrophages are prompted to release iron to upload circulating Tf and support the erythron. In HC, they may be prompted to release iron (despite high Tf saturation) because of the faulty TfR1 cycle due to a mutated HFE (Fig. 1) . In this context, it is intriguing that in a mouse model of HC (the ␤2-M knockout mice) in which introduction of a normal monocytemacrophage population by fetal liver cell transplantation was able to modify the iron-deficient phenotype of hepatic Kupffer cells (again supporting the proposed model of a primary defect of macrophages in HC) but was unable to normalize iron absorption (84) . This reinforces the concept stressed in this article that the defect in HC is shared by both macrophages and intestinal cells, but the latter are the final effectors of an increased iron absorption due to inability to sense the saturated levels of iron in the circulation and to modify accordingly the absorption machinery (Fig. 1) . Recent studies in the USF2 knockout mice suggest that hepcidin might serve as store regulator (64) . This needs to be confirmed in the hepcidin knockout mice, when available, and in specific studies addressing hepcidin effect on iron uptake and trafficking. Hypothetically, hepcidin may play a regulatory role in iron metabolism either in inflammatory states or also under other circumstances. If so, hepcidin could easily fit the above model if its function is to cooperate with the circulating iron Tf in signaling to macrophages and crypt cells through TfR HFE. Within this framework, increased hepcidin serum levels during inflammation and iron overload would facilitate the transfer of this signal to enhance iron retention in RE cells and crypt cells, and the latter event will eventually lead to decreased iron absorption. In hereditary HC, this signaling will be impaired by the faulty TfR-HFE function. In this context, it is intriguing that in the USF2 knockout mice, the phenotype is similar to HC with low iron in RE cells and parenchymal iron overload. Therefore, whereas in HC, it is the lack of functional HFE that impairs the signaling to crypt and RE cells in the presence of functional hepcidin and TfR, in the USF2 knockout mice, it is the lack of hepcidin that negatively affects appropriate signaling, despite a functional HFE and TfR.
It has become apparent that mutations in HFE do not account for all cases of HC, particularly in southern Europe. A study of Italian patients showed that only 64% were homozygous for HFE C282Y mutations (74) , and the estimated prevalence of C282Y homozygosity in the general Italian population is 1 in 3,900 (18) .
At least two genes have been associated with non-HFE-linked HC, TfR2, and SLC11A3 (coding for ferroportin1/IREG1/MTP1). Patients with an autosomal recessive iron-loading disorder similar to HC carry mutations in TFR2 gene (16) . Despite the intriguing homology with TFR1, TFR2 is not regulated by iron chelation, and it remains unclear how mutations in TFR2 lead to HC because available studies indicate that TfR2 does not bind HFE and is not expressed in the crypt cells (33) . Recently, a new clinical entity has been characterized in which the clinical phenotype may be confused with classic HC, but the disorder shows autosomal dominant inheritance, and the patients do not have mutations in HFE. Additional distinguishing features are anemia early in life, despite increased serum Ft levels and early iron accumulation in reticuloendothelial cells. The disorder is due to mutations in ferroportin1/IREG1/MTP1 (61, 65) . It has been suggested that the mutation results in a loss of function, causing a mild but significant impairment of iron recycling by reticuloendothelial macrophages (61); iron retention by macrophages would lead to decreased availability of iron for circulating Tf (in fact, Tf saturation is inappropriately low compared with serum Ft levels in this disease) and for the hematopoietic system. This, in turn, would activate feedback mechanisms to increase intestinal absorption and compensate the underlying anemia, eventually leading to iron overload.
For many years, fundamental questions on the regulation of iron metabolism and trafficking in humans have remained unanswered. The discovery of the HC (HFE) gene and the advent of molecular genetics have dramatically changed our concepts of these complex processes. It easy to predict that when further genetically engineered animals will be available, such as the knockout mice for ferroportin1/IREG1/MTP1, TfR2, and hepcidin, their study will provide the few missing pieces of the puzzle and help to finally define the molecular pathogenesis of hereditary HC.
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